论文部分内容阅读
胃癌是世界范围内最常见的恶性肿瘤之一,由于胃癌患者的体力状况和治疗耐受性均较差,经过一线化疗方案失败后,选择晚期胃癌的二线化疗方案,甚至多线化疗方案应更为慎重。我科2012年3月开始收治11例HER-2高表达的晚期胃癌患者,二线化疗后进展,接受白蛋白结合型紫杉醇联合曲妥珠单抗方案治疗,疗效确切,毒副反应轻,现报告如下。1资料与方法1.1临床资料11例不能手术或术后复发的晚期
Gastric cancer is one of the most common malignancies in the world. Due to the poor physical condition and treatment tolerance of patients with gastric cancer, after the first-line chemotherapy fails, second-line chemotherapy for advanced gastric cancer or even multi-line chemotherapy should be more Be careful. 11 cases of advanced gastric cancer with high expression of HER-2 were treated in our hospital from March 2012, and progressed after second-line chemotherapy. The treatment with albumin-bound paclitaxel combined with trastuzumab has definite curative effect and light toxicity. as follows. 1 Materials and Methods 1.1 Clinical data 11 cases of late surgery or postoperative recurrence